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and speciﬁcity) using ANCOVA, and construct validity using
exploratory factor analysis with varimax rotation. RESULTS:
Eighty-ﬁve students (2A = 47; 2B = 38) completed the study.
Baseline HRQL was not statistically different. The reliability
coefﬁcient for the instrument was higher than 80%. ANCOVA
showed reasonable responsiveness, i.e., statistically signiﬁcant
differences between Scenario 1–2A and no differences between
Scenario 1–2B, as expected. Factor analysis indicated 7 factors;
some modiﬁcation would be needed in two of the items. 
CONCLUSION: Initial validation of an HRQL instrument for
multiple chronic conditions indicated good reliability and
responsiveness; however minor modiﬁcations would be needed
to improve construct validity before the instrument is ready for
use in a MTM clinic.
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OBJECTIVES: The Kansas City Cardiomyopathy Questionnaire
(KCCQ) is a valid, reliable and sensitive measure through which
to quantify heart failure (HF) patients’ health status (symptoms,
function and quality of life). Prior to its use in an international
clinical trial of HF patients, the original 23-item KCCQ needed
to be translated into 30 languages/cultures. METHODS: The
original instrument was developed in US English, with input
from Mapi Research Institute on the best terminology to facili-
tate future translations. To ensure conceptual equivalence and
cultural relevance, the translation process was conducted by spe-
cialists in each target country across the EU, CEE, and Latin
America, using the following standardized methodology: 1) two
independent forward translations by professional translators
who were native speakers of the target language and ﬂuent in
English; 2) comparison and reconciliation of the translations by
the specialist in the target country and the translators; 3) back-
ward translation by a native English speaker; 4) comparison of
source and backward version with the original KCCQ developer;
5) review by a clinician; 6) comprehension test on 5 HF patients;
and 7) international harmonization. RESULTS: The translation
process revealed challenges where the formulation of the origi-
nal items made use of speciﬁc examples to describe an item
concept. Since a literal translation of these speciﬁc examples was
not always culturally relevant, these speciﬁc examples were
replaced by generic terms. After completing these changes and
international harmonization, all 30 versions were certiﬁed by
Mapi to be conceptually equivalent to the original questionnaire
and culturally relevant for each country. CONCLUSION: The
KCCQ, translated into 30 languages, can be used as a valid and
reliable instrument to evaluate HF patients’ health status glob-
ally. Harmonization of these versions will facilitate international
comparison of results and pooling of data when used in inter-
national studies involving quantiﬁcation of HF patients’ health
status.
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OBJECTIVES: To document the recent dynamic changes in
prevalence of obesity and medical comorbidities and costs for
the U.S. general population. METHODS: This study analyzed
data from the 2000 and 2004 Medical Expenditure Panel Survey
(MEPS), a nationally representative panel data. Based on Body
Mass Index (BMI), weight groups were deﬁned as Underweight
(UW, BMI < 18.5), Normal Weight (NW, BMI 18.5–24.9), Over-
weight (OW, BMI 25–29.9), Obese I (BMI 30–34.9), Obese II
(BMI 35–39.9), and Obese III (BMI <= 40). Univariate analyses
were conducted to examine changes in obesity prevalence, as
well as the trend differentials in demographic and socioeconomic
status. Trends in co-morbidities and medical costs were com-
pared among different weight groups across years. All estimates
are weighted to be nationally representative. RESULTS: The
prevalence of obesity increased from 22.5% to 25.9% between
year 2000 and 2004 (Obese I: 14.6% vs 16.4%, Obese II: 5.1%
vs 6.1%, and Obese III: 2.8% vs 3.4%). Obesity increased more
among African-Americans, individuals who had higher educa-
tion, higher income, and public health insurance. For both years,
obesity was consistently associated with the greatest risk of dia-
betes, high blood pressure, cardiovascular disease, asthma and
joint pain (p > 0.001). In 2000 dollars, the change in total
medical costs was from $3159 in 2000 to $3854 in 2004 for
obese groups; $2324 to $3000 for NW; and $2345 to $3088 
for OW, all at highly signiﬁcant level of p < 0.001. Obesity
related physician ofﬁce-based costs, ER costs and RX costs were
also increased as compared to other groups (p < 0.001). CON-
CLUSION: The prevalence of obesity has increased since 2000,
resulting in an increase in obesity related comorbidities and
medical costs. This study also showed that obesity may be asso-
ciated with race, socioeconomic status, education, and health
insurance.
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OBJECTIVES: The incretin mimetic exenatide improves gly-
caemic control with associated weight reduction in patients with
type 2 diabetes (T2DM) treated with metformin (MET), a
sulphonylurea (SU), or both. As pharmacokinetics and pharma-
codynamics for a given drug can vary with age, we explored exe-
natide’s efﬁcacy and safety for different age groups. METHODS:
Patients who completed 2 y of exenatide treatment in this interim
analysis (N = 283, 63% male, age 57.3 ± 9.7 y; weight 100 ±
19 kg, HbA1c 8.3 ± 1.0%, fasting plasma glucose [FPG] 9.7 ±
2.5 mmol/L, duration of diabetes 8.1 ± 6.1 y, mean ± SD) had
statistically signiﬁcant (P < 0.05) mean (±SE) reductions in HbA1c
(−1.1 ± 0.1%), FPG (−1.4 ± 0.2 mmol/L), and weight (−4.7 ±
0.3 kg). RESULTS: When examined by baseline age (<45 y, n =
26, 45–54 y, n = 91, 55–64 y, n = 97, ≥65 y, n = 69), mean (±SE)
reductions in HbA1c> (−1.1 ± 0.2%, −1.0 ± 0.1%, −1.3 ± 0.1%,
and −1.2 ± 0.1%, respectively), weight (−3.6 ± 1.0 kg, −4.6 ±
0.7 kg, −4.9 ± 0.6 kg, and −4.9 ± 0.6 kg), and FPG (−1.1 ±
0.4 mmol/L, −1.1 ± 0.3 mmol/L, −1.7 ± 0.3 mmol/L, and −1.5 
± 0.3 mmol/L) were not age dependent. Overall, 54% (N = 283)
of eligible patients completed 2 y of exenatide, with withdrawal
of consent (15%) and adverse event (9%) the most common
reasons for withdrawal. Completion rates varied by age group
(35%, 51%, 58%, and 68%), as did the frequency of those with-
drawing due to adverse events (4%, 7%, 11%, and 11%) and
withdrawal of consent (19%, 18%, 15%, and 8%). Nausea was
the most common adverse event for all age groups. Incidence of
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hypoglycaemia was no higher for those ≥65 y, with one case of
severe hypoglycaemia in a subject <65 y also treated with an SU.
CONCLUSION: In summary, in this ongoing open-label exten-
sion study, 2 y of exenatide treatment demonstrated similar
durable improvements in glycaemic control and weight reduc-
tion and safety proﬁles for those subjects ≥65 y compared to
younger subjects with T2DM treated with MET and/or SU.
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OBJECTIVES: The purpose of this study was to evaluate the
relationship between various diabetes treatment regimens and 1)
attainment of hemoglobin A1C (HbA1c) treatment goal, and 2)
treatment costs. METHODS: Pharmacy, medical, and laboratory
claims data from a large health plan in the Southeastern US from
1/1/2003–7/31/2006 were used. The index date was deﬁned as
the date of the last available HbA1c value, an indicator of
glycemic control during the previous 90 days. The study period
was deﬁned as the 120-day period that preceded the index date.
Goal was deﬁned as an HbA1c < 7.0. Treatment regimens were
categorized based on the number of diabetes-related medica-
tions: 1 oral, 2 orals, ≥3 orals, insulin, insulin plus 1 oral, insulin
plus 2 orals, and insulin plus ≥3 orals. Logistic and OLS regres-
sion models were used to identify predictors of goal attainment
and total treatment costs, respectively, after adjusting for poten-
tial confounding variables. RESULTS: A total of 18,905 patients
were included in the study, of which 50.9% were at goal. The
highest proportion of patients at goal was in the 1 oral group
(63.1%), while insulin plus 1 oral had the lowest (22.0%). After
adjusting for potential confounders, patients treated with regi-
mens that included insulin had a higher HbA1c value than those
only treated with oral medications. Those treated with insulin
were less likely to be at goal compared to those treated with one
oral (OR = 0.18, p < 0.0001). Similar results were found in other
insulin treatment groups. Predictors of increased total cost
included male sex, higher co-morbidity scores, and treatment
with multiple oral medications compared to one oral medication.
Increased compliance was associated with goal attainment (p <
0.0001) and lower total cost (p < 0.004). CONCLUSION: Only
50% of patients attained HbA1c goal. Increased compliance was
associated with goal attainment and lower costs.
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OBJECTIVES: Diabetes Mellitus II is one of the fastest growing
diseases in western countries. In Hungary about 5% of the pop-
ulation is diagnosed with DM II. Younger generations are at risk
of this disease when they eat unhealthy and physical activity
gains less attention in their life style. The objective of the study
is to measure the effect of dance as an aerobe movement on the
blood sugar level and compliance to medical therapy of adult
patients with DM type II. METHODS: The experimental study
design was used. 30 patients were selected randomly from the
Diabetes Club of Baranya County Hospital. Detailed medical
examination was carried out before and after the program. The
movement therapy program consisted of by the patients most
loved transformed dance styles based on the principles of phys-
iotherapy and coaching theories used by Beamer (2003). Muscle
strengthening and muscle mass improving techniques were used,
too. The actual blood sugar level and HbA1c level were moni-
tored during the 16 weeks program before and after the physi-
cal activity. For the statistical analysis Chi-square tests were used
with SPSS 11.0. RESULTS: The average age was 61.5 years
(Rmax:53;Rmin:75). In spite of the small sample size there is a
signiﬁcant change in the average blood sugar level between the
ﬁrst and the 16th weeks (p < 0.001). Due to the four-month
therapy, HbA1c level and actual blood sugar level remained in
the normal range. More than three days of break in the program
decreases the coaching effect signiﬁcantly. CONCLUSION:
Changing the health behavior and compliance among the elder
patients with DM II is difﬁcult. A “dance” coaching program
carried out with an appropriate intensity and frequency can com-
plete the medical therapy and rehabilitation of diabetes mellitus
type II effectively. The program can increase the well-being and
compliance of DM II patients.
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OBJECTIVES: Long-term studies of rosiglitazone (ADOPT) and
pioglitazone (PROactive) have reported average weight gain of
4.8 kgs and 3.6 kgs, respectively. This study assessed weighted
average gain in the body weight of type 2 diabetic patients due
to the use of thiazolidinediones (TZDs) over a short duration.
METHODS: Meta-analysis of published rosiglitazone and
pioglitazone clinical trials with duration up to 52 weeks. Initially,
trials with placebo as well as active comparator arms were iden-
tiﬁed through a systematic search of PubMed, EBSCO and 
Sci-lit databases. Each trial arm was treated as an independent
observation. Wherever possible, placebo-subtracted weight
change was computed for each arm of TZD trials. Exploratory
regression analysis was conducted using backward elimination
method to identify predictors of weighted average gain in the
body weight. RESULTS: Overall, 43 TZD trials yielded 60 trial
arms which represented 8,322 patients. Out of these, only 13
trial arms provided information sufﬁcient to compute the
placebo-subtracted weight gain. Weighted placebo-subtracted
gain in the body weight due to TZDs was 3.22 ± 7.16 kg. Sig-
niﬁcant predictors (b ± SE) of placebo-subtracted weight gain
(adjusted R2 = 0.73) were the use of TZDs as monotherapy (1.04
± 0.36), duration of diabetes in the treatment group in years
(0.25 ± 0.06) and rosiglitazone dose of 8 mg (1.36 ± 0.26). CON-
CLUSION: Patients using TZDs recorded mean weight gain of
3.22 ± 7.16 kg during short-term placebo-controlled clinical
trials. Duration of diabetes, use of TZD as monotherapy and
rosiglitazone dose of 8 mg were the only signiﬁcant predictors of
placebo-subtracted gain in the body weight. This weight gain is
highly undesirable in diabetics, due to high risk of experiencing
a cardiovascular event and potential adherence problems.
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